TTM
78.0%
YoY change
−1.32pp
Trough year (2000)
47.4%
Peak year (2024)
79.5%
Latest annual
78.1%
Gross Margin history chart for Edwards Lifesciences (EW) from 1999 to 2025
Latest: 78.1%
Gross Margin change chart for Edwards Lifesciences (EW) from 1999 to 2025
Latest: −1.32pp
Gross Margin history table for Edwards Lifesciences (EW) from 1999 to 2025
| 2025 | 78.1% | -1.32pp | ||
| 2024 | 79.5% | +0.16pp | ||
| 2023 | 79.3% | +0.98pp | ||
| 2022 | 78.3% | +1.74pp | ||
| 2021 | 76.6% | +1.63pp | ||
| 2020 | 74.9% | +1.52pp | ||
| 2019 | 73.4% | -1.80pp | ||
| 2018 | 75.2% | +0.93pp | ||
| 2017 | 74.3% | +1.49pp | ||
| 2016 | 72.8% | +0.25pp | ||
| 2015 | 72.6% | -0.27pp | ||
| 2014 | 72.8% | -0.58pp | ||
| 2013 | 73.4% | +0.09pp | ||
| 2012 | 73.3% | +0.77pp | ||
| 2011 | 72.5% | +0.89pp | ||
| 2010 | 71.7% | +2.24pp | ||
| 2009 | 69.4% | +2.46pp | ||
| 2008 | 67.0% | +1.91pp | ||
| 2007 | 65.1% | +2.02pp | ||
| 2006 | 63.0% | +0.58pp | ||
| 2005 | 62.5% | +2.20pp | ||
| 2004 | 60.3% | +2.02pp | ||
| 2003 | 58.2% | +0.72pp | ||
| 2002 | 57.5% | +4.34pp | ||
| 2001 | 53.2% | +5.79pp | ||
| 2000 | 47.4% | -1.12pp | ||
| 1999 | 48.5% | — |
- 202578.1%-1.32pp
- 202479.5%+0.16pp
- 202379.3%+0.98pp
- 202278.3%+1.74pp
- 202176.6%+1.63pp
- 202074.9%+1.52pp
- 201973.4%-1.80pp
- 201875.2%+0.93pp
- 201774.3%+1.49pp
- 201672.8%+0.25pp
- 201572.6%-0.27pp
- 201472.8%-0.58pp
- 201373.4%+0.09pp
- 201273.3%+0.77pp
- 201172.5%+0.89pp
- 201071.7%+2.24pp
- 200969.4%+2.46pp
- 200867.0%+1.91pp
- 200765.1%+2.02pp
- 200663.0%+0.58pp
- 200562.5%+2.20pp
- 200460.3%+2.02pp
- 200358.2%+0.72pp
- 200257.5%+4.34pp
- 200153.2%+5.79pp
- 200047.4%-1.12pp
- 199948.5%—
Gross Margin values are taken from Edwards Lifesciences's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Gross Margin at Edwards Lifesciences (EW)
According to Edwards Lifesciences's latest reported financial statements, the company's latest reported gross margin is 78.0%. Gross margin is gross profit divided by revenue, expressed as a percentage. It shows how much of each sales dollar survives the direct cost of goods sold — before operating expenses, interest, and taxes. A higher gross margin generally signals pricing power and production efficiency. Margins are most meaningful compared against sector peers and a company's own history.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Edwards Lifesciences (EW) reported gross margin of 78.13% – contracted 1.3 percentage points year-over-year.
2024 marks the peak gross margin at 79.46%, with the historical low of 47.39% recorded in 2000.
Edwards Lifesciences Gross Margin by Year
Edwards Lifesciences Gross Margin 2025: 78.1%
2025's gross margin for Edwards Lifesciences came in at 78.13%, contracted 1.3 percentage points from 2024.
Edwards Lifesciences Gross Margin 2024: 79.5%
Edwards Lifesciences posted gross margin of 79.46% in 2024, expanded 0.2 percentage points from 2023. This figure represents the highest annual value in the available history.
Edwards Lifesciences Gross Margin 2023: 79.3%
In 2023, Edwards Lifesciences reported gross margin of 79.30%, expanded 1.0 percentage points from 2022.
Edwards Lifesciences Gross Margin 2022: 78.3%
Edwards Lifesciences gross margin in 2022 was 78.31%, expanded 1.7 percentage points from 2021.
Edwards Lifesciences Gross Margin 2021: 76.6%
Edwards Lifesciences gross margin in 2021 was 76.57%.
See more financial history for Edwards Lifesciences (EW).
Sector peers by Gross Margin
Healthcare peers of Edwards Lifesciences (EW), ranked by their latest gross margin
| 83.5% | |
| 81.8% | |
| 81.7% | |
| 75.9% | |
| 71.5% | |
| 70.7% | |
| 70.0% | |
| 18.8% |
- 83.5%
- 81.8%
- 81.7%
- 75.9%
- 71.5%
- 70.7%
Frequently asked questions
Edwards Lifesciences (EW) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation